Survodutide (BI 456906) is a novel subcutaneous GCGR/GLP-1R dual agonist in development for the treatment of people with type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.